Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Report 2026

Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Overview

• Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor market size has reached to $1.25 billion in 2025 • Expected to grow to $2.01 billion in 2030 at a compound annual growth rate (CAGR) of 9.9% • Growth Driver: Rising Parkinson's Disease Prevalence Driving Growth In The Market • Market Trend: Innovative Capsule Formulations In The Market • North America was the largest region in 2025.

What Is Covered Under Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

A vesicular monoamine transporter 2 (VMAT2) inhibitor is a drug that blocks VMAT2, a protein responsible for transporting monoamines (dopamine, serotonin, norepinephrine) into synaptic vesicles for release in the brain. VMAT2 inhibitors are utilized to manage neurological and psychiatric disorders by reducing excessive neurotransmitter release, particularly dopamine, to treat conditions such as tardive dyskinesia, Huntington’s disease, and other hyperkinetic movement disorders. The main drugs in the vesicular monoamine transporter 2 (VMAT2) inhibitor are tetrabenazine, deutetrabenazine, valbenazine, and other drugs. Tetrabenazine is a VMAT2 inhibitor used to treat movement disorders by reducing dopamine levels in the brain. These drugs are administered through various routes, such as oral and other administrations, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. They are used for various applications, including Huntington’s disease, tardive dyskinesia, and other conditions. The primary end users of these drugs include hospitals, homecare settings, specialty clinics, and other healthcare facilities.

What Is The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Growth Forecast?

The vesicular monoamine transporter 2 (vmat2) inhibitor market size is expected to see strong growth in the next few years. It will grow to $2.01 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to growing tardive dyskinesia prevalence, expansion of deutetrabenazine usage, rising neurological disorder awareness, growth of specialty neurology clinics, increased oral drug preference. Major trends in the forecast period include rising use of targeted neurotransmitter modulation, increasing treatment of tardive dyskinesia, expansion of oral neurological therapies, growing focus on movement disorder management, increased adoption of long-term neurology drugs.

Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Segmentation

1) By Drugs: Tetrabenazine, Deutetrabenazine, Valbenazine, Other Drugs 2) By Route Of Administration: Oral, Other Administrations 3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy 4) By Application: Huntington’s Disease, Tardive Dyskinesia, Other Applications 5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Tetrabenazine: Huntington’s Disease Treatment, Tardive Dyskinesia Management, Tourette Syndrome Treatment 2) By Deutetrabenazine: Huntington’s Disease Chorea, Tardive Dyskinesia Treatment, Off-Label Movement Disorders 3) By Valbenazine: Tardive Dyskinesia Treatment, Tourette Syndrome Research, Other Hyperkinetic Movement Disorders 4) By Other Drugs: Investigational VMAT2 Inhibitors, Emerging Therapies For Movement Disorders, Off-Label Use In Neurological Conditions

What Is The Driver Of The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

The increasing prevalence of parkinson’s disease is expected to propel the growth of the vesicular monoamine transporter 2 (VMAT2) inhibitor market going forward. Parkinson's disease refers to a progressive neurological disorder that affects movement due to the loss of dopamine-producing cells in the brain. The increasing prevalence of parkinson's disease is mainly due to an aging population, better diagnosis, environmental factors such as toxins, genetic influences, and greater awareness of the condition. VMAT2 inhibitors help manage Parkinson's symptoms by controlling dopamine release and reducing tremors and dyskinesia. For instance, in October 2025, according to the Parkinson's UK, a UK-based research and support charity, by 2030, Parkinson’s cases in the UK are expected to reach 173,000, and around 28,000 people are projected to be diagnosed in 2025, which means one new diagnosis every 20 minutes as the population grows and ages. Therefore, the increased prevalence of Parkinson’s disease is driving growth in the vesicular monoamine transporter 2 (VMAT2) inhibitor industry.

Key Players In The Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market

Major companies operating in the vesicular monoamine transporter 2 (vmat2) inhibitor market are Neurocrine Biosciences Inc., H. Lundbeck A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Bausch Health Companies Inc., Luye Pharma Group Ltd., Mitsubishi Tanabe Pharma Corporation, Sumitomo Dainippon Pharma, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eli Lilly and Company, Merck KGaA, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Biogen Inc

Global Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Trends and Insights

Major companies operating in the vesicular monoamine transporter 2 (VMAT2) inhibitors market are focusing on developing innovative formulations such as capsules to enhance patient compliance, improve drug stability, and optimize therapeutic efficacy. Capsules, a solid dosage form enclosed in a gelatin or HPMC shell, help VMAT2 inhibitors by improving drug stability, ensuring precise dosing, and enhancing patient compliance. For instance, in July 2024, Neurocrine Biosciences Inc., a US-based biopharmaceutical company, launched Ingrezza Sprinkle (valbenazine) capsules, a new formulation of the VMAT2 inhibitor Ingrezza designed to ease administration for adults with tardive dyskinesia and chorea associated with Huntington's disease who experience dysphagia or difficulty swallowing. Ingrezza Sprinkle offers the same effective dosing options as Ingrezza and can be administered by sprinkling the contents of the capsule onto soft food or by swallowing the capsule whole.

What Are Latest Mergers And Acquisitions In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. With this acquisition, Bristol Myers Squibb aims to strengthen its neurology portfolio by gaining access to Karuna Therapeutics' promising pipeline of innovative treatments, including the VMAT2 inhibitor KarXT, which has the potential to address unmet needs in psychiatric disorders such as schizophrenia, thereby expanding its therapeutic offerings and accelerating growth in the neuroscience sector. Karuna Therapeutics is a US-based biopharmaceutical company that offers vesicular monoamine transporter 2 (VMAT2) inhibitor treatment.

Regional Insights

North America was the largest region in the vesicular monoamine transporter 2 (VMAT2) inhibitor market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market?

The vesicular monoamine transporter 2 (VMAT2) inhibitor market consists of sales of products such as deutetrabenazine, valbenazine, and tetrabenazine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Report 2026?

The vesicular monoamine transporter 2 (vmat2) inhibitor market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vesicular monoamine transporter 2 (vmat2) inhibitor industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.